Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
- Written by PR Newswire
- Novartis obtains rights to develop and commercialize subcutaneous formulations for multiple products utilizing ALT-B4
- Alteogen's fourth licensing agreement signed this year further accelerating the expansion of the Hybrozyme™ platform
DAEJEON, South Korea, Sept. 2, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170), a leading...














